News

More in News

• Novavax's COVID-flu combo vaccine shows strong immune response in trial

  The study, which involved about 2,000 participants, tested the safety and immune response of the COVID-influenza combination and standalone flu vaccines compared to its COVID-19 shot Nuvaxovid and Sanofi's flu shot Fluzone HD, respectively.

  

• CDMO OneSource obtains Xbrane biosimilars' manufacturing contract

  According to OneSource, the drugmaker biosimilar's respective reference products have an estimated annual sales of around ₹2.23 lakh crore.

  

• Recursion to lay off 20% of workforce amid biotech funding woes

  Recursion is trying to "reduce the complexity, especially in the context of a challenging and frictional capital markets environment, so that every dollar drives real return on investment (ROI) for our investors and for patients," CEO Christopher Gibson told Reuters.

  

• JP MorganChase President Daniel Pinto joins J&J board of directors

  Pinto will hold the post of President till June 30 and 2025, and will retire from the company at the end of 2026.

  

• Bayer extends research collaboration with Broad Institute to pump Cardio pipeline

  Currently, the drugmaker is focusing on developing potential treatment options for patients with specific forms of cardiovascular disease such as dilated cardiomyopathy (DCM).

  

• FDA closes inspection of Zydus API facility, indicates voluntary actions

  This facility underwent an inspection from 21st to 25th April 2025 and has been classified as Voluntary Action Indicated (VAI). FDA confirmed the inspection as “closed”.

  

• Pharma body opposes entry curbs on medical representatives, seeks rethink

  In a representation to the health ministry and department of pharmaceutical (DoP), IPA has said the diktat will impact of growth of pharmaceutical sector and result in job losses of medical representatives.

  

• Dozens of states sue to block sale of 23andMe personal genetic data without customer consent

  Regeneron Pharmaceuticals said last month it aimed to buy the company for USD 256 million. Regeneron said it would comply with 23andMe's privacy policies and applicable law.

  

• Indian pharma firms not copying products, India respect IP rights, says Goyal

  The ministry has earlier also criticised attempts by certain firms to secure pharmaceutical patents through minor incremental innovations.

  

• Novo Nordisk starts new CagriSema weightloss drug trial

  The company had positioned CagriSema as a more potent successor to its blockbuster obesity shot Wegovy, boosting market expectations that its weight-loss potential was greater than that of U.S. drugmaker Eli Lilly's rival drug Mounjaro.

  

• Drug pricing reform talks with US government lack clarity, industry executives say

  Davis added that Merck has discussed how to share the cost of drug innovation, both in the United States and other countries, with the administration.

  

• US FDA pauses Gilead trials testing experimental HIV pill combination

  The paused trials included two mid-to-late studies, and three more in the early phase, the company said. The mid-to-late stage trials were testing the oral combination treatment against Biktarvy, Gilead's once-a-day pill to treat HIV.

  

• Insmed's blood pressure drug meets main goal in mid-stage trial

  The drug, treprostinil palmitil, is a once-daily therapy that is inhaled through a device. The 120-patient study found that the drug helped reduce blood pressure in the patients' lungs by 35 per cent, compared with a placebo.

  

• Hims & Hers says its weight-loss business can grow as US market changes

  Hims also sells liraglutide, a generic version of an older Novo diabetes drug that also causes weight loss, as well as branded Wegovy and Eli Lilly's rival Zepbound.

  

• Obesity injections may have fewer weight loss effects in real world compared to trials, study says

  Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment.

  

• CDMO OneSource flagship plant clears FDA inspection

  The inspection was conducted in March following which the US drug regulator had issued a form 483 with four observations. Later based on the company's response and commitments, the agency has classified the inspection outcome as Voluntary Action Indicated.

  

• SMA blockbuster Risdiplam tablet version receives approval in Europe

  Initially the drug was marketed in a powder form which requires a specified administration procedure while the latest approved 5mg tablet can either be swallowed whole or dispersed in water and does not require refrigeration.

  

• Molecular Partners to cut workforce by a quarter

  The company, which develops DARPin protein therapeutics - a new type of engineered protein drugs - said the cuts aim to extend its cash runway into 2028, beyond earlier guidance of 2027.

  

• Lilly’s Weight Loss Blockbuster cuts Heart Failure risk by 38%, halves Hospitalizations

  In a Phase 3 study the US drugmaker reported that, among obese people tirzepatide reduces the risk of heart failure by 38 per cent and reduces risk of hospitalization for heart failure by 56 per cent.

  • Exclusive

  

• CRO Parexel completes registration in India

  The registration is in-line with the the new statutory regulation, which mandates all CROs operating in India to register with CDSCO.